Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug

Tanaka, Yoshimasa; Iwasaki, Masashi; Murata-Hirai, Kaoru; Matsumoto, Kenji; Hayashi, Kosuke; Okamura, Haruki; Sugie, Tomoharu; Minato, Nagahiro; Morita, Craig T.; Toi, Masakazu

doi:10.1038/s41598-017-05553-0

Download PDF

Article
Open access
Published: 20 July 2017

Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug

Yoshimasa Tanaka^1,2,3,
Masashi Iwasaki¹,
Kaoru Murata-Hirai¹,
Kenji Matsumoto¹,
Kosuke Hayashi¹,
Haruki Okamura⁴,
Tomoharu Sugie⁵,
Nagahiro Minato²,
Craig T. Morita⁶ &
…
Masakazu Toi⁵

Scientific Reports volume 7, Article number: 5987 (2017) Cite this article

3665 Accesses
46 Citations
9 Altmetric
Metrics details

Subjects

Abstract

Bisphosphonates have benefits in breast cancer and multiple myeloma patients and have been used with adoptive immunotherapy with γδ T cells expressing Vγ2 Vδ2 TCRs. Although treatment with γδ T cells is safe, it has shown limited efficacy. Present bisphosphonates stimulate γδ T cells but were designed to inhibit bone resorption rather than treating cancer and have limited oral absorption, tumor cell entry, and cause bone side effects. The development of phosphate and phosphonate nucleotide prodrugs has led to important drugs for hepatitis C and HIV. Using a similar approach, we synthesized bisphosphonate prodrugs and found that they efficiently limit tumor cell growth. Pivoxil bisphosphonate esters enter cells where esterases convert them to their active acids. The bisphosphonate esters stimulated γδ T cells to secrete TNF-α in response to a variety of tumor cells more efficiently than their corresponding acids. The most active compound, tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate (7), specifically expanded γδ T cells and stimulated them to secrete interferon-γ and kill tumor cells. In preclinical studies, combination therapy with compound 7 and γδ T cells prolonged survival of mice inoculated with either human bladder cancer or fibrosarcoma cells. Therefore, bisphosphonate prodrugs could enhance the effectiveness of adoptive cancer immunotherapy with γδ T cells.

Immunomodulatory effects of pevonedistat, a NEDD8-activating enzyme inhibitor, in chronic lymphocytic leukemia-derived T cells

Article 16 March 2020

Scott Best, Vi Lam, … Alexey V. Danilov

Bispecific antibody targeting both B7-H3 and PD-L1 exhibits superior antitumor activities

Article 16 June 2023

Hua-ying Li, Yi-li Chen, … Chun-he Wang

Proof-of-principle studies on a strategy to enhance nucleotide imbalance specifically in cancer cells

Article Open access 24 November 2022

Twana Alkasalias, Juan Zhang, … Sonia Laín

Introduction

Geminal bisphosphonates with P-C-P structure were initially developed as anti-corrosion agents for industrial purposes¹. The first-generation bisphosphonates such as etidronate and clodronate show high affinity for bone minerals and are metabolized to cytotoxic β, γ-methylene analogs of ATP in osteoclasts². Extensive synthetic efforts resulted in second-generation bisphosphonates with alkylamine side chains and third-generation bisphosphonates with nitrogen-containing heterocyclic side chains for the treatment of patients with osteoporosis and hypercalcemia of malignancy³.

These nitrogen-containing bisphosphonates enter monocyte-lineage cells (including osteoclasts) as well as tumor cells where they inhibit farnesyl diphosphate synthase (FDPS)^{4, 5}. FDPS inhibition reduces the levels of its downstream metabolites, farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP), and leads to the production of a toxic ATP analog, triphosphoric acid 1-adenosin-5′-yl ester 3-(3-methylbut-3-enyl) ester (ApppI)⁶. The loss of FDPS metabolites impairs their transfer to the C-termini of small GTPases, such as RAS, RAP, RHO, and RAB, and the γ subunit of G protein-coupled receptors, that is required for their functions in signal transduction and cell survival.

Inhibition of FDPS also leads to the accumulation of its upstream metabolite, isopentenyl pyrophosphate (diphosphate) (IPP)^7,8,9, which in turn stimulates cytotoxic γδ T cells through their Vγ2 Vδ2 TCRs by the sensing of IPP binding to the B30.2 domain of butyrophilin (BTN) 3A1^{10,11,12,13,14}. These activated γδ T cells exhibit potent cytotoxic activity against bisphosphonates-pulsed tumor cells¹⁵.

The addition of intravenous zoledronic acid to standard therapies improves disease-free survival of breast cancer patients in a low estrogen environment^16,17,18 and overall survival of multiple myeloma patients¹⁹ and lung cancer patients²⁰. The use of oral bisphosphonates (alendronate or risedronate) also improves survival of breast cancer patients²¹. The anti-tumor activity of bisphosphonates is likely mediated through several pathways; one possible pathway is by promoting the anti-tumor activity of γδ T cells.

γδ T cells bearing Vγ2 Vδ2 TCRs have been targeted for cancer immunotherapy in two ways. In one approach, Vγ2Vδ2 T cells are directly stimulated in vivo either by an IPP analog or an aminobisphosphonates in conjunction with IL-2^{22,23,24,25,26}. This approach has had limited success because expansion of Vγ2Vδ2 T cell does not always occur and because deletion and/or anergy of Vγ2Vδ2 T cells rapidly develops. A second approach has been the ex vivo expansion of Vγ2Vδ2 T cells followed by their adoptive transfer^{27,28,29,30,31,32,33,34,35,36}. This approach avoids the development of anergy by harvesting and freezing of PBMC prior to therapy or by avoiding the use of intravenous bisphosphonates. However, the most successful clinical trials have used intravenous zoledronic acid around the time of adoptive transfer of Vγ2Vδ2 T cells.

One potential way to improve γδ T cell immunotherapy is to increase the potency of the bisphosphonate used by facilitating tumor cell entry. Oldfield and co-workers have improved the activity of bisphosphonates by incorporating long acyl chains^{37, 38} or by masking the P-C-P structure with pivoxil esters³⁹. Pivoxil bisphosphonate esters have also been used to inhibit geranylgeranyl diphosphate synthase⁴⁰. Similar masking of the negative charges of the phosphate moieties of nucleotides to make prodrugs has greatly improved their effectiveness in treating hepatitis C and human immunodeficiency virus infections^{41, 42}.

We recently synthesized pivaloyloxymethyl (pivoxil) derivatives of bisphosphonates⁴³. The resulting bisphosphonate prodrugs were efficiently internalized into tumor cells where intracellular esterases converted them into biologically active bisphosphonic acids that block FDPS. FDPS inhibition slows tumor growth through inhibition of prenylation of signal transduction molecules (schematic is shown in Fig. 1). Blocking of FDPS will also increase IPP levels in tumor cells which should make them stimulatory for Vγ2Vδ2 T cells through their Vγ2 Vδ2 TCRs.

In this study, we have assessed the ability of these bisphosphonate prodrugs to stimulate γδ T cells and to inhibit prenylation in a variety of tumor cell lines. Bisphosphonate prodrugs potently stimulated γδ T cells with pretreatment of the different cell lines. A thiazole bisphosphonate prodrug, 7, showed the highest potency for stimulation of γδ T cells and inhibition of RAP1A prenylation. 7 specifically stimulated Vγ2Vδ2 T cells to expand from blood lymphocytes, secrete IFN-γ, and kill tumor cells. In preclinical studies, 7 combined with Vγ2Vδ2 T cells prolonged survival of immunodeficient NOG mice implanted with either human bladder cancer or fibrocarcinoma cells more than Vγ2Vδ2 T cells alone.

Results

Enhancement of TNF-α secretion from γδ T cells by pivaloyloxymethylation of bisphosphonates

We previously showed that masking the phosphonate charges of bisphosphonates by pivoxil groups greatly enhanced their ability to inhibit tumor cell growth⁴³. To determine if the stimulation of Vγ2Vδ2 T cells showed similar enhancement, EJ-1 bladder carcinoma cells were treated with seven bisphosphonate prodrugs or their corresponding active acid forms (Supplemental Fig. S1). Five of these pairs (2–6/9–13) were based on NE11809 (compound 8)^{44, 45}. A final compound substituted a thiazole for the pyridine group. Their synthesis has been described⁴³. All of the bisphosphonate prodrugs stimulated TNF-α secretion from γδ T cells more effectively than their corresponding acid forms (Fig. 2). For example, compound 7 was 1,100-fold more active than its acid, 14 (Fig. 2D). Bisphosphonate prodrug concentrations required to stimulate half-maximal TNF-α production (EC₅₀) from γδ T cells were between 20-fold to 1,100-fold lower than their acid forms (Supplemental Table S1) with several (5, 6, and 7) active at less than 80 nM. These differences were larger than the values we previously reported for growth inhibition of EJ-1 cells with eight of the nine pivoxil esters active at lower concentrations⁴³.

Based on these findings, we tested 28 additional bisphosphonate pivoxil and other esters (compounds 15–42, Supplemental Fig. S2) for their ability to stimulate TNF-α release by γδ T cells. Again 7 was the most potent although its methyl- derivative (34) had similar activity as did compound 39, another analog of 8, that is similar in structure and potency to 5 and 6 (Supplemental Table S2). Given that compound 7 was the most active for γδ T cell activation and tumor growth inhibition⁴³, we focused on it for further study.

γδ T cell activation by compound 7

7 was also more active than its acid form, 14, in stimulating release of TNF-α by Vγ2Vδ2 T cells upon testing an additional 21 tumor cell lines, ranging from 81-fold to 1,900-fold more potent (Table 1 and Supplemental Fig. S3). 7 was further tested against a variety of tumor cell lines in comparison to zoledronic acid, the most potent FDA-approved bisphosphonate (Fig. 3 and Supplemental Table S3). The EC₅₀ values for most tumor cell lines were less than 1 μM (Fig. 3) and 76 out of 77 tumor cell lines elicited TNF-α responses by Vγ2Vδ2 T cells. The proportion of tumor cell lines with EC₅₀ values of 100 nM or less was 57.1% for lymphoma, 85.7% for myeloid leukemia, 14.3% for mammary carcinoma, and 51.9% for other tumor cell lines. The average EC₅₀ ± S.D. was 157 ± 170 nM for lymphomas, 96 ± 91 nM for myeloid leukemias, 465 ± 290 nM for mammary carcinomas, and 298 ± 240 nM for other tumor cell lines. These values were significantly lower than those for zoledronic acid, where the average EC₅₀ ± S.D. was 367,571 ± 173,160 nM (2,337-fold greater than that of compound 7) for lymphomas, 240,571 ± 219,133 nM (2,495-fold) for myeloid leukemias, 187,771 ± 191,657 nM (404-fold) for mammary carcinomas, and 52,223 ± 82,697 nM (190-fold) for other tumor cell lines⁴⁶. Thus, 7 is a significantly more potent activator of γδ T cells than zoledronic acid.

Table 1 Effect of pivoxil esterification of 14 on TNF-α secretion from γδ Τ cells stimulated with bisphosphonate-pretreated tumor cells.

Full size table

Inhibition of RAP1A-geranylgeranylation in tumor cells by compound 7

Bisphosphonates indirectly stimulate Vγ2Vδ2 T cells by inhibiting FDPS resulting in the intracellular accumulation of IPP, its upstream metabolite. The binding of IPP to the B30.2 domain of BTN3A1 alters cells in an undefined way to make them stimulatory for Vγ2Vδ2 T cells^{7, 9}. Additionally, downstream metabolites such as geranylgeranyl diphosphate and farnesyl diphosphophate, are depleted leading to the accumulation of unprenylated RAP1A, a small G protein required for cellular adhesion. Therefore, the accumulation of unprenylated RAP1A is a measure of FDPS inhibition (Supplemental Fig. S4). To confirm that 7 uses the same mechanism of action as other bisphosphonates, the concentration of compound 7 required for half-maximal inhibition (IC₅₀) of RAP1A prenylation was determined for a variety of tumor cell lines (Fig. 4 and Supplemental Table S3). 7 was highly active at inhibiting the prenylation of RAP1A with six cell lines with IC₅₀ values < 10 nM, the P31/FUJ and MONO-1 monocyte-like leukemia cells, the EJ-1 and T24 bladder carcinoma cells, the 786-0 renal cell carcinoma cells, and the KATOIII gastric carcinoma cells. The proportion of tumor cell lines with an IC₅₀ of 100 nM or less was 71.4% for lymphoma, 85.7% for myeloid leukemias, 42.9% for mammary carcinomas, and 32.7% for other tumor cell lines (Fig. 4). The average IC₅₀ ± S.D. were similar to those noted for stimulating TNF-α release with values of 115 ± 115 nM for lymphomas, 107 ± 197 nM for myeloid leukemias, 1,099 ± 1,965 nM for mammary carcinomas, and 386 ± 259 nM for other tumor cell lines. Again, the values for zoledronic acid, were much higher than those for 7 (Fig. 4D), with an average IC₅₀ ± S.D. of 372,286 ± 164,995 nM (3,233-fold greater than that of compound 7) for lymphomas, 281,129 ± 229,049 nM (2,626-fold) for myeloid leukemias, 163,143 ± 191,842 nM (149-fold) for mammary carcinomas, and 64,249 ± 172,850 nM (166-fold) for other tumor cell lines⁴⁶. Therefore, similar to the EC₅₀ values noted for stimulating TNF-α release, 7 was a highly potent inhibitor of RAP1A prenylation. Given that most strong inhibitors of GGPS have mono- or diacyl- chains to occupy the farensyl and/or the geranyl sites^47,48,49, the activity of 7 is likely due to inhibition of FDPS.

To assess the degree of correlation between compound 7 activities, the concentrations of compound 7 required for γδ T cell activation (EC₅₀) were correlated with those for FDPS inhibition (IC₅₀) or for tumor growth inhibition for each of the tumor cell lines (Supplemental Table S3). Only tumor cell growth inhibition and TNF-α release (r = 0.282, p = 0.016) were significantly correlated for compound 7 (Supplemental Fig. S5, top left panel). The concentrations of compound 7 required to stimulate production of TNF-α release were not significantly correlated with those required for RAP1A inhibition nor were tumor cell growth inhibition and RAP1A inhibition correlated. In contrast, zoledronic acid exhibited highly significant correlations for cell inhibition and TNF-α stimulation (r = 0.454, p < 0.0001), cell inhibition and RAP1A inhibition (r = 0.556, p < 0.0001), and TNF-α stimulation and RAP1A inhibition (r = 0.499, p < 0.0001). Also, 7 and zoledronic acid activities were not significantly correlated (Supplemental Fig. S5). Because the pivoxil esters must be removed to activate 7, the lack of correlation between most activities of 7 could reflect differences in esterase expression in the tumor cell lines or other factors besides FDPS inhibition that determine its activity. The activity of zoledronic acid, in contrast, is likely dependent primarily on FDPS inhibition. Hence, the high correlation for the three activities measured.

Specific stimulation of γδ T cells expressing Vγ2 Vδ2 TCRs by compound 7

To assess the specificity of stimulation by compound 7, PBMC were cultured with 7 and the levels of Vγ2Vδ2 T cells determined after 14 days. Despite the presence of other γδ and αβ T cells, only Vγ2Vδ2 T cells were selectively expanded to 98.8% of cells (Fig. 5A). The expansion of Vγ2Vδ2 T cells also demonstrates that compound 7 is not severely toxic to monocytes given that this response is dependent on their activity^{50, 51}. To determine the specificity of compound 7 on cellular cytotoxicity of γδ T cells, their activity against T-47D mammary carcinoma cells was tested in a real-time cell growth assay. Exposure of T-47D mammary carcinoma cells to 50 nM of compound 7 did not affect their growth while exposure to γδ T cells slightly delayed their growth. In contrast, the addition of both compound 7 and γδ T cells to cultures of T-47D cells inhibited their growth in a compound 7 dose-dependent manner (Fig. 5B). Additionally, pretreatment of U937 histocytoma cells with compound 7 rendered them stimulatory for Vγ2Vδ2 T cell degranulation and surface expression of CD107a (Fig. 5C). Finally, compound 7 stimulated Vγ2Vδ2 T cells in PBMC to release interferon-γ (IFN-γ) (Fig. 5D). These results demonstrate that γδ T cells expressing Vγ2 Vδ2 TCRs are specifically activated to proliferate, kill tumor cells, and release IFN-γ by exposure to monocytes and tumor cells treated with 7.

Cancer therapy combining compound 7 and adoptive transfer of Vγ2Vδ2 T cells improves the survival of immunodeficient NOG mice inoculated with either human EJ-1 bladder carcinoma cells or HT1080 fibrosarcoma cells

Because BTN3A1 proteins and IPP-responsive γδ T cells are not present in mice, rats, guinea pigs, or rabbits, adoptive transfer models for human γδ T cell immunotherapy were developed. Immunodeficient NOG (NOD.Cg-Prkdc ^scid Il2rg ^tm1Sug/Jic) mice were intraperitoneally inoculated with either human EJ-1 bladder carcinoma cells or human HT1080 fibrosarcoma cells. Tumor-bearing mice were then injected twice a week with either (1) PBS, (2) compound 7, (3) γδ T cells, or (4) γδ T cells and compound 7 until mouse death or euthanasia. The Vγ2Vδ2 T cells were derived from a single donor by stimulation with zoledronic acid, frozen for use, and were between 95–98% pure (Supplemental Fig. S6). Mice inoculated with EJ-1 cells survived longer when treated with γδ T cells and compound 7 (median survival 76 days) than with γδ T cells alone (median survival 60 days) (Fig. 6A, p = 0.0076). No increase in survival was noted after treatment with 7 compared with control mice (median survival 53 days versus 50.5 days for PBS, p = 0.4348). Similar results were noted with a second solid tumor, the HT1080 fibrosarcoma. Mice treated with γδ T cells and compound 7 survived longer (median survival 73.5 days) than mice treated with γδ T cells alone (median survival 47.5 days) (Fig. 6B, p = 0.0008). Treatment with compound 7 alone did not prolong mouse survival (median survival 33.5 days versus 37 days for PBS, p = 0.2879). 7 was well tolerated with no obvious morbidity and no mortality of mice given a 3–15-fold higher doses than those used in these experiments (Supplemental Fig. S7). These results show that combined treatment with γδ T cells and compound 7 improves survival of mice bearing two different human tumors and that a variety of tumors would be potentially responsive to treatment.

Discussion

Adoptive immunotherapy with Vγ2Vδ2 T cells for cancer has proven to be safe but of limited effectiveness. Treatment has resulted in partial and complete remissions and stable disease but most patients progress. In this study, we describe a new approach to therapy with Vγ2Vδ2 T cells by using bisphosphonate prodrugs where the phosphonate moiety is masked with pivoxil groups. Masking the phosphonate moiety greatly increases the potency of bisphosphonate stimulation of Vγ2Vδ2 T cells with several active at less than 100 nM. A thaizole compound, 7 (tetrakis-pivaloyloxymethyl 2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate), was particularly active, stimulating TNF-α release by Vγ2Vδ2 T cells at concentrations as low as 40 nM. 7 was significantly more potent than zoledronic acid at stimulating Vγ2Vδ2 T cells with an average EC₅₀ that is 909-fold lower than zoledronic acid. Consistent with FDPS inhibition as its mechanism of action, 7 exhibited potent inhibitory activity for RAP1A prenylation in tumor cells (3,200-fold more active than zoledronic acid) and tumor cell growth⁴³ (184-fold more potent than zoledronic acid). Like other FDPS inhibitors, 7 selectively stimulated Vγ2Vδ2 T cells to proliferate, secrete cytokines, and kill tumor cells treated with 7. Finally, combined therapy with 7 and Vγ2Vδ2 T cells extended the survival of immunodeficient mice inoculated with either human bladder carcinoma or fibrosarcoma cells. Taken together, our results suggest that the bisphosphonate prodrug, 7, could significantly improve the efficacy of adoptive immunotherapy with Vγ2Vδ2 T cells.

To improve the activity of bisphosphonates, we designed and synthesized a series of bisphosphonate prodrugs⁴³. In the present study, we have assessed bisphosphonate prodrug activation of Vγ2Vδ2 T cells and inhibition of RAP1A prenylation in response to a variety of human cancer cell lines pretreated with the compounds. Masking the negative charges of the phosphonate groups of bisphosphonates with pivoxil esters greatly increased their activity. However, biological activity varied between tumor cell lines. These variations could be explained by differences in the levels of intracellular esterase activity and/or in the substrate specificity of the esterases^{52, 53}. Additionally, differences in the levels of FDPS and which oncogenes were driving tumor cell proliferation and function could also play a role in determining their sensitivity to bisphosphonate prodrugs. Compound 7, a thiazole bisphosphonate prodrug, was highly active against most tumor cell lines. Hematopoietic cell lines were particularly sensitive to 7 averaging 796-fold more sensitive to 7 than zoledronic acid for growth inhibition, 3,487-fold more active for TNF-α release by γδ T cells than zoledronic acid, and 12,869-fold more inhibitory for RAP1A prenylation than zoledronic acid. Thus, the bisphosphonate prodrug 7 could be particularly effective for the treatment of lymphomas and myeloid leukemias.

One of the most important features of bisphosphonate prodrugs is their high membrane permeability that enables them to enter into tumor cells that have poor fluid-phase endocytosis. Because they were developed as anti-resorptive therapeutics, conventional bisphosphonates interact with hydroxyapatide crystals of bone with high affinity. In contrast, because of their hydrophobicity, bisphosphonate prodrugs will likely have low affinity for bone and, instead, distribute to non-skeletal tissues including tumors. The high membrane permeability and non-skeletal distribution of bisphosphonate prodrugs are ideal for their use in cancer immunotherapy targeting γδ T cells.

Clinical trials using adoptive immunotherapy with Vγ2Vδ2 T cells to treat various cancers have not routinely used bisphosphonate treatments to increase tumor immunogenicity^{27,28,29,30,31,32,33,34,35,36}. However, the adoptive immunotherapy trials reporting the best results have also used zoledronic acid treatment. A complete remission in a patient with metastatic renal cell carcinoma (out of eleven patients treated) was achieved by treatment with intravenous zoledronic acid and IL-2 followed by adoptive transfer of Vγ2Vδ2 T cells on the same day and then intravenous IL-2 given for four consecutive days repeated monthly for six cycles⁵⁴. In a second trial, there were no responses noted in patients treated with zoledronic acid and γδ T cells alone but one complete remission was achieved in a breast cancer patient treated with a combination of zoledronic acid and adoptive transfer of Vγ2Vδ2 T cells along with the continuation of hormonal therapy³⁰. Partial or complete responses were also noted in patients with various solid tumors when chemotherapy was combined with the adoptive transfer of Vγ2Vδ2 T cells with³⁰ or without³⁵ zoledronic acid. Although stable disease was achieved in a number of patients with lung cancer⁵⁵ and other solid tumors^{31, 35, 36}, the most common response to the adoptive transfer of γδ T cells alone was progressive disease. Therefore, the combination of a nitrogen-containing bisphosphonate and γδ T cells appears more effective than either alone.

Combining bisphosphonate prodrugs with γδ T cells could significantly advance the use of γδ T cells for cancer immunotherapy for a wide range of tumors. Given the potency of compound 7 both for stimulating γδ T cells and for inhibiting tumor cell growth and its likely lowered bone binding and increased entry into rapidly metabolizing tumor cells compared with zoledronic acid, combination therapy with 7 and the adoptive transfer of γδ T cells could increase treatment efficacy. As shown in our study, Vγ2Vδ2 T cells respond to essentially all tumors after treatment with compound 7 irrespective of the number of mutations the tumor harbors. Unlike TIL or CAR-T therapy, successful Vγ2Vδ2 T cell adoptive transfer does not require preconditioning with chemotherapy or irradiation. Therefore, therapy with 7 and γδ T cells could be further combined with checkpoint blockade with anti-PD-1/anti-PD-L1 and/or anti-CTLA-4 antibodies to activate anti-tumor CD4 and CD8 αβ T cells that are already present. Other cancer immunotherapies such as indoleamine 2,3-dioxygenase inhibitors^56,57,58 or COX1/2 blockers to inhibit prostaglandin E₂ production⁵⁹ could also be added. In summary, combining the bisphosphonate prodrug 7 and γδ T cells with other cancer immunotherapies could allow the treatment of a wide range of adult and pediatric solid tumors that are not presently amendable to successful chemotherapy or targeted therapy.

Materials and Methods

Synthesis of bisphosphonate prodrugs and their corresponding acid forms

The synthesis and chemical characterization of the bisphosphonate prodrugs and their acids used in these studies are described⁴³.

Expansion of Vγ2Vδ2 T cells

Peripheral blood samples were obtained after approval of the institutional review board of Kyoto University Hospital and with written informed consent from all participants. All methods were performed in accordance with the relevant guidelines and regulations of Kyoto University Hospital. PBMCs were purified by Ficoll-Paque^TM PLUS (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) gradient centrifugation. The cells were washed two times with PBS, then resuspended in modified Yssel’s medium supplemented with 10% human AB serum (Cosmobio Co., Ltd., Koto-ku, Tokyo, Japan). They were cultured for 10 days at 2.5 × 10⁶ cells/1.5 ml in modified Yssel’s medium with 5 μM zoledronic acid and 100 IU/ml IL-2 (Shionogi Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan) in a 24-well plate (Corning Inc., Corning, NY, USA). The culture medium was replaced every day from day 2 with fresh medium containing IL-2. The resulting expanded Vγ2Vδ2 T cells were then stored in liquid nitrogen for use upon thawing in in vitro assays or adoptive immunotherapy.

TNF-α release by Vγ2Vδ2 T cells

Tumor cell lines were grown, harvested, and resuspended at 1 × 10⁶ cells/0.5 ml in 10-fold serial dilutions of BP prodrugs or acid forms of BPs in complete RPMI 1640 media (Sigma, St. Louis, MO, USA) supplemented with 10% fetal calf serum (Sigma), 10⁻⁵ M 2-mercaptoethanol (Nacalai Tesque, Kyoto, Japan), 100 IU/ml penicillin (Meiji Seika Kaisha, Tokyo, Japan), and 100 μg/ml streptomycin (Meiji Seika Kaisha). After incubation at 37 °C with 5% CO₂ for 4 h, the cells were washed three times with 5 ml of the medium and resuspended in 0.5 ml of the same medium. A total of 0.1 ml (2 × 10⁵ cells/well) of the tumor cell suspension was placed on flat-bottomed 96-well plates and 0.1 ml of γδ T cells (2 × 10⁵ cells/well) was added. The plates were incubated at 37 °C with 5% CO₂ for 16 h and the culture supernatants stored overnight at −80 °C. The samples were then thawed and TNF-α concentrations determined by ELISA (Peprotech, Rocky Hill, NJ, USA) using an ARVO spectrophotometer (PerkinElmer, Foster City, CA, USA). All experiments were performed in triplicate. Because bisphosphonic acids are not efficiently internalized into some tumor cells and were sometimes cytotoxic to tumor cells at 0.1 mM or greater, it was difficult to calculate EC₅₀ values for some cell lines. In these cases, the value at 0.1 mM was considered to be the maximum value and used to calculate arbitrary EC₅₀ values.

Inhibition of geranylgeranylation of RAP1A in tumor cells

Tumor cells were resuspended in 90 ml of complete RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS, Sigma), 10⁻⁵ M 2-mercaptoethanol (Invitrogen, Carlsbad, CA, USA), 100 IU/ml of penicillin (Meiji Seika Kaisha, Ltd., Chuo-Ku, Tokyo, Japan), and 100 μg/ml of streptomycin (Meiji Seika Kaisha) and grown overnight at 37 °C with 5% CO₂ in 225 cm² flasks. Compound 7 was then added to the flasks to the concentrations indicated above. After incubation for 16 h, the cells were harvested and resuspended in 100 μl of lysis solution containing 1% NP-40 (Wako Pure Chemical Industries Ltd., Chuo-ku, Osaka, Japan), 0.1% sodium dodecyl sulfate (SDS) (Tokyo Chemistry Industry Co., Ltd., Chuo-Ku, Tokyo, Japan), and 0.5% sodium deoxycholate (Wako) in microcentrifuge tubes. After centrifugation at 15,000 rpm for 10 min, the supernatants were transferred to new tubes and SDS-urea buffer containing 6.7 M urea (Wako), 5% SDS, 100 mM Tris–HCl buffer, pH 7.4 (Wako), 0.25% bromophenol blue (Wako), and 50 mM dithiothreitol (Wako) was added to give a protein concentration of 5 mg/ml. The samples were loaded on 15% polyacrylamide slab gels (Daiichi Pure Chemicals Co., Ltd., Chuo-ku, Tokyo, Japan) at 50 μg/lane, and electrophoresed at 120 mA/h. The proteins were then transferred onto Polyscreen (R) PVDF Transfer Membranes (PerkinElmer Inc., Waltham, MA) treated with goat anti-unprenylated RAP1A mAb (1 to 500 dilution, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), and horse radish peroxidase-conjugated anti-goat IgG mAb (1 to 5,000 dilution, KPL Inc., Gaithersburg, MD, USA), followed by SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA). Although not shown, controls using goat anti-RAP1A and anti-GAPDH mAbs (Santa Cruz Biotechnology) were included in this study. Chemiluminescence was detected on Amersham Hyperfilm^TM MP (GE Healthcare Ltd., Little Chalfont, Buckinghamshire, UK) using a Fuji Medical Film Processor FPM100 (Fuji Film Co., Ltd., Ashigara, Kanagawa, Japan). The strength of the signal for each protein band was determined by the brightness of the corresponding part of the image scanned using a LAS-4000 Mini Luminescent Image Analyzer (Fuji Film Co., Ltd.). The dose-response curves are based on the digitalized data.

γδ T cell activation assays

For expansion of Vγ2Vδ2 T cells, PBMC from healthy donors were cultured at 2.5 × 10⁶ cells/1.5 ml in modified Yssel’s medium in the presence of 1 μM compound 7 in a 24-well plate (Corning Inc., Corning, NY, USA). The culture medium was replaced on day 2 with fresh medium containing IL-2. The cells were passaged on days 7, 9, 10, 11, and 12 and IL-2 (100 IU/ml) was added to the culture medium every day beginning from day 1. On day 14, the cells were harvested and analyzed for the expression of CD3 and Vδ2 by flow cytometry. For measurement of interferon-γ (IFN-γ) release, PBMC from healthy donors were cultured at 2.5 × 10⁶ cells/1.5 ml in modified Yssel’s medium in the presence of 1 μM compound 7 at 37 °C with 5% CO₂ in a 24-well plate (Corning Inc., Corning, NY, USA). After 24 h, 100 IU/ml IL-2 (Shionogi Pharmaceutical Co., Ltd., Chuo-ku, Osaka, Japan) was added to the culture medium. After an additional 24 h, the culture supernatants were removed and stored overnight at −80 °C. The samples were then thawed and IFN-γ levels determined by ELISA (Peprotech, Rocky Hill, NJ, USA). All experiments were performed in triplicate.

Inhibition of in vitro tumor cell growth by compound 7 and Vγ2Vδ2 T cells

Inhibition of cell growth by compound 7 and Vγ2Vδ2 T cells was measured using a real-time cell analyzer (RTCA) system comprising a 96-well E-plate with impedance sensors. Tumor cells were cultured for 24 h, harvested using 0.25% trypsin-EDTA solution (Invitrogen Gibco), and plated into 96-well E-plates at a density of 3 × 10³ cells/100 μl/well. Impedance was monitored every 15 min for 46.5 h at 37 °C with 5% CO₂. 50 μl of supernatant was then removed from, and 50 μl of a serial dilution of compound 7 was added to each well. The plates were returned to the RTCA unit and incubated at 37 °C with 5% CO₂ for 3.5 h. After 50 μl of the supernatant was removed, 1 × 10⁵ Vγ2Vδ2 T cells/50 μl were added to each well. Impedance was monitored for an additional 15 h. Five independent replicate experiments were performed, with eight wells per treatment group used in each individual replicate experiment.

CD107a degranulation assay

Vγ2Vδ2 T cells (2 × 10⁵ cells/well) were incubated with U937 cells (2 × 10⁵ cells/well) that had been treated with serial dilutions of compound 7 for 2 h at 37 °C in 50 μl of complete RPMI 1640 medium in a 96-well culture plate in the presence of 5 μl of phycoerythrin-conjugated anti-CD107a mAb (BioLegend, San Diego, CA, USA) at 37 °C with 5% CO₂. After 4 h of incubation, the cells were stained with 50 μl of 25-fold diluted FITC-conjugated anti-Vδ2 mAb fluorescein isothiocyanate-conjugated anti-TCR-Vδ2 mAb (Immunotech, Prague, Czech Republic) and analyzed using a FACSCalibur flow cytometer. The proportion of CD107a⁺ cells in Vδ2⁺ cells was plotted against concentrations of compound 7.

Inhibition of tumor cell growth by treatment with compound 7 and γδ T cells in NOG immunodeficient mice

Immunodeficient NOG (NOD.Cg-Prkdc ^scid Il2rg ^tm1Sug/Jic) female mice 7–8 weeks of age were intraperitoneally (i.p.) inoculated with either 1.0 × 10⁶ EJ-1 bladder cancer cells or 1.0 × 10⁶ HT1080 fibrosarcoma cells that had been stably transfected with pGL4.10[luc2] (Promega) to express the luc2 luciferase protein. On day 3 and 6, tumor-bearing mice were i.p. injected with either (1) 0.1 ml of PBS, (2) 2 μg (for EJ-1) or 10 μg (for HT1080) compound 7, (3) 2 × 10⁷ γδ T cells, or (4) 2 × 10⁷ γδ T cells plus 2 μg (for EJ-1) or 10 μg (for HT1080) compound 7. A dose of 2 μg of compound 7 corresponds to 97 μg/kg whereas 10 μg corresponds to 485 μg/kg. These treatment regimens were repeated for the duration of the experiment. Survival of the mice was recorded and plotted using Prism version 4.0 c. Vγ2Vδ2 T cells were expanded for 10 days from PBMC from a single donor with breast cancer as described above and frozen for use. Purity of the Vγ2Vδ2 T cells was between 95–98%. Animal use was approved by the institutional review board of Kyoto University Medical School. All methods were performed in accordance with the relevant guidelines and regulations of Kyoto University Medical School.

Statistical analyses

The statistical significance of survival data was assessed using the log-rank test. The p values are shown in the figure. The Pearson correlation coefficient was determined by correlating the different biological activities of compound 7 and zoledronic acid. p < 0.05 was considered significant. Statistical analyses were done in Prism version 4.0c (GraphPad Software, La Jolla, CA).

References

Fleisch, H. Development of bisphosphonates. Breast Cancer Res. 4, 30–34 (2002).
Article CAS PubMed Google Scholar
Lehenkari, P. P. et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol. Pharmacol. 61, 1255–1262 (2002).
Article CAS PubMed Google Scholar
Russell, R. G. Bisphosphonates: mode of action and pharmacology. Pediatrics 119(Suppl 2), S150–162 (2007).
Article MathSciNet PubMed Google Scholar
Bergstrom, J. D., Bostedor, R. G., Masarachia, P. J., Reszka, A. A. & Rodan, G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch. Biochem. Biophys. 373, 231–241 (2000).
Article CAS PubMed Google Scholar
van Beek, E., Pieterman, E., Cohen, L., Lowik, C. & Papapoulos, S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem. Biophys. Res. Commun. 264, 108–111 (1999).
Article PubMed Google Scholar
Mönkkönen, H. et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147, 437–445 (2006).
Article PubMed PubMed Central Google Scholar
Gober, H.-J. et al. Human T cell receptor gd cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197, 163–168 (2003).
Article CAS PubMed PubMed Central Google Scholar
Thompson, K. & Rogers, M. J. Statins prevent bisphosphonate-induced g,d-T-cell proliferation and activation in vitro. J. Bone Miner. Res. 19, 278–288 (2004).
Article CAS PubMed Google Scholar
Wang, H. et al. Indirect stimulation of human Vg2Vd2 T cells through alterations in isoprenoid metabolism. J. Immunol. 187, 5099–5113 (2011).
Article CAS PubMed PubMed Central Google Scholar
Harly, C. et al. Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human gd T-cell subset. Blood 120, 2269–2279 (2012).
Article CAS PubMed PubMed Central Google Scholar
Wang, H. et al. Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vg2Vd2 T cells. J. Immunol. 191, 1029–1042 (2013).
Article CAS PubMed Google Scholar
Sandstrom, A. et al. The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vg9Vd2 T cells. Immunity 40, 490–500 (2014).
Article CAS PubMed PubMed Central Google Scholar
Wang, H. & Morita, C. T. Sensor function for butyrophilin 3A1 in prenyl pyrophosphate stimulation of human Vg2Vd2 T Cells. J. Immunol. 195, 4583–4594 (2015).
Article CAS PubMed PubMed Central Google Scholar
Hsiao, C.-H. C. et al. Synthesis of a phosphoantigen prodrug that potently activates Vg9Vd2 T-lymphocytes. Chem. Biol. 21, 945–954 (2014).
Article CAS PubMed Google Scholar
Kato, Y., Tanaka, Y., Miyagawa, F., Yamashita, S. & Minato, N. Targeting of tumor cells for human gd T cells by nonpeptide antigens. J. Immunol. 167, 5092–5098 (2001).
Article CAS PubMed Google Scholar
Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679–691 (2009).
Article CAS PubMed Google Scholar
Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631–641 (2011).
Article CAS PubMed Google Scholar
Coleman, R. et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann. Oncol. 24, 398–405 (2013).
Article CAS PubMed Google Scholar
Morgan, G. J. et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376, 1989–1999 (2010).
Article CAS PubMed Google Scholar
Zarogoulidis, K. et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int. J. Cancer 125, 1705–1709 (2009).
Article CAS PubMed Google Scholar
Rennert, G. et al. Oral bisphosphonates and improved survival of breast cancer. Clin. Cancer Res. 23, 1684–1689 (2017).
Article CAS PubMed Google Scholar
Wilhelm, M. et al. gd T cells for immune therapy of patients with lymphoid malignancies. Blood 102, 200–206 (2003).
Article CAS PubMed Google Scholar
Dieli, F. et al. Targeting human gd T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res. 67, 7450–7457 (2007).
Article CAS PubMed PubMed Central Google Scholar
Meraviglia, S. et al. In vivo manipulation of Vg9Vd2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161, 290–297 (2010).
CAS PubMed PubMed Central Google Scholar
Lang, J. M. et al. Pilot trial of interleukin-2 and zoledronic acid to augment gd T cells as treatment for patients with refractory renal cell carcinoma. Cancer Immunol. Immunother. 60, 1447–1460 (2011).
Article CAS PubMed PubMed Central Google Scholar
Kunzmann, V. et al. Tumor-promoting versus tumor-antagonizing roles of gd T cells in cancer immunotherapy: results from a prospective phase I/II trial. J. Immunother. 35, 205–213 (2012).
Article CAS PubMed Google Scholar
Bennouna, J. et al. Phase-I study of Innacell gd, an autologous cell-therapy product highly enriched in g9d2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol. Immunother. 57, 1599–1609 (2008).
Article CAS PubMed Google Scholar
Abe, Y. et al. Clinical and immunological evaluation of zoledronate-activated Vg9gd T-cell-based immunotherapy for patients with multiple myeloma. Exp. Hematol. 37, 956–968 (2009).
Article CAS PubMed Google Scholar
Sakamoto, M. et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gd T cells: a phase I clinical study. J. Immunother. 34, 202–211 (2011).
Article CAS PubMed Google Scholar
Nicol, A. J. et al. Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br. J. Cancer 105, 778–786 (2011).
Article CAS PubMed PubMed Central Google Scholar
Kobayashi, H., Tanaka, Y., Yagi, J., Minato, N. & Tanabe, K. Phase I/II study of adoptive transfer of gd T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol. Immunother. 60, 1075–1084 (2011).
Article CAS PubMed Google Scholar
Noguchi, A. et al. Zoledronate-activated Vg9dδ T cell-based immunotherapy is feasible and restores the impairment of gd T cells in patients with solid tumors. Cytotherapy 13, 92–97 (2011).
Article CAS PubMed Google Scholar
Izumi, T. et al. Ex vivo characterization of gd T-cell repertoire in patients after adoptive transfer of Vg9Vd2 T cells expressing the interleukin-2 receptor g-chain and the common g-chain. Cytotherapy 15, 481–491 (2013).
Article CAS PubMed Google Scholar
Wada, I. et al. Intraperitoneal injection of in vitro expanded Vg9Vd2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med. 3, 362–375 (2014).
Article CAS PubMed PubMed Central Google Scholar
Okawaki, M., Hironaka, K., Yamanura, M. & Yamaguchi, Y. Adoptive immunotherapy using autologous lymphocytes activated ex vivo with antigen stimulation for patients with incurable cancer. Kawasaki Med. J. 40, 33–39 (2014).
Google Scholar
Yamaguchi, Y., Katata, Y., Okawaki, M., Sawaki, A. & Yamamura, M. A prospective observational study of adoptive immunotherapy for cancer using zoledronate-activated killer (ZAK) cells - An analysis for patients with incurable pancreatic cancer. Anticancer Res. 36, 2307–2313 (2016).
Article CAS PubMed Google Scholar
Zhang, Y. et al. Lipophilic pyridinium bisphosphonates: potent gd T cell stimulators. Angew Chem Int Ed 49, 1136–1138 (2010).
Article CAS Google Scholar
Zhang, Y. et al. Chemo-immunotherapeutic anti-malarials targeting isoprenoid biosynthesis. ACS Med. Chem. Lett. 4, 423–427 (2013).
Article CAS PubMed PubMed Central Google Scholar
Zhang, Y. et al. Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines. J. Med. Chem. 49, 5804–5814 (2006).
Article CAS PubMed Google Scholar
Wiemer, A. J. et al. Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation. Bioorg. Med. Chem. 16, 3652–3660 (2008).
Article CAS PubMed Google Scholar
Wiemer, A.J. & Wiemer, D.F. Prodrugs of phosphonates and phosphates: crossing the membrane barrier. Top. Curr. Chem. (2014).
Hecker, S. J. & Erion, M. D. Prodrugs of phosphates and phosphonates. J. Med. Chem. 51, 2328–2345 (2008).
Article CAS PubMed Google Scholar
Matsumoto, K. et al. Targeting cancer cells with a bisphosphonate prodrug. ChemMedChem 11, 2656–2663 (2016).
Article CAS PubMed Google Scholar
Rogers, M. J. et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol. Pharmacol. 47, 398–402 (1995).
CAS PubMed Google Scholar
Dunford, J. E. et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296, 235–242 (2001).
CAS PubMed Google Scholar
Idrees, A. S. et al. Comparison of gd T cell responses and farnesyl diphosphate synthase inhibition in tumor cells pretreated with zoledronic acid. Cancer Sci 104, 536–542 (2013).
Article CAS PubMed PubMed Central Google Scholar
Szabo, C. M. et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J. Med. Chem. 45, 2185–2196 (2002).
Article CAS PubMed Google Scholar
Wiemer, A. J., Yu, J. S., Lamb, K. M., Hohl, R. J. & Wiemer, D. F. Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors. Bioorg. Med. Chem. 16, 390–399 (2008).
Article CAS PubMed Google Scholar
Chen, C. K.-M. et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates: a crystallographic and computational investigation. J. Med. Chem. 51, 5594–5607 (2008).
Article CAS PubMed Central Google Scholar
Miyagawa, F., Tanaka, Y., Yamashita, S. & Minato, N. Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gd T cells by aminobisphosphonate antigen. J. Immunol. 166, 5508–5514 (2001).
Article CAS PubMed Google Scholar
Roelofs, A. J. et al. Peripheral blood monocytes are responsible for gd T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br. J. Haematol. 144, 245–250 (2009).
Article PubMed PubMed Central Google Scholar
Hosokawa, M. et al. Genomic structure and transcriptional regulation of the rat, mouse, and human carboxylesterase genes. Drug Metab. Rev. 39, 1–15 (2007).
Article MathSciNet CAS PubMed Google Scholar
Hosokawa, M. Structure and catalytic properties of carboxylesterase isozymes involved in metabolic activation of prodrugs. Molecules 13, 412–431 (2008).
Article CAS PubMed Google Scholar
Kobayashi, H., Tanaka, Y., Shimmura, H., Minato, N. & Tanabe, K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gd T-cells in a patient with renal cell carcinoma. Anticancer Res. 30, 575–579 (2010).
CAS PubMed Google Scholar
Kakimi, K., Matsushita, H., Murakawa, T. & Nakajima, J. gd T cell therapy for the treatment of non-small cell lung cancer. Transl. Lung Cancer Res. 3, 23–33 (2014).
CAS PubMed PubMed Central Google Scholar
Holmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D. & Allison, J. P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210, 1389–1402 (2013).
Article CAS PubMed PubMed Central Google Scholar
Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8⁺ T cells directly within the tumor microenvironment. J. Immunother. Cancer 2, 3 (2014).
Article PubMed PubMed Central Google Scholar
Liu, X. et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115, 3520–3530 (2010).
Article CAS PubMed Google Scholar
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

The authors are grateful to Ms. Chiyomi Inoue for her technical assistance. This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, Culture, Sports, and Technology of Japan (MEXT) (to Y.T.), by “Special Coordination Funds for Promoting Science and Technology” from MEXT and Astellas Pharma Inc. through the “Formation of Center for Innovation by Fusion of Advanced Technologies” program (to Y.T.), by “Platform for Drug Discovery, Informatics, and Structural Life Science” from MEXT (to Y.T.), and by grants from the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development Grant 2I01 BX000972-05) and the National Institutes of Health (National Cancer Institute, Grants CA097274 (University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence) and P30 CA086862 (Core Support)) (to C.T.M.). C.T.M. is the Kelting Family Scholar in Rheumatology. The content of this manuscript are solely the responsibility of the authors and do not necessarily represent the official views of the granting agencies.

Author information

Authors and Affiliations

Center for Innovation in Immunoregulative Technology and Therapeutics, Graduate School of Medicine, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan
Yoshimasa Tanaka, Masashi Iwasaki, Kaoru Murata-Hirai, Kenji Matsumoto & Kosuke Hayashi
Department of Immunology and Cell Biology, Graduate School of Medicine, Kyoto University, Yoshidakonoe-cho, Sakyo-ku, Kyoto, 606-8501, Japan
Yoshimasa Tanaka & Nagahiro Minato
Center for Bioinformatics and Molecular Medicine, Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
Yoshimasa Tanaka
Department of Tumor Immunology and Cell Therapy, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan
Haruki Okamura
Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan
Tomoharu Sugie & Masakazu Toi
Department of Internal Medicine and the Interdisciplinary Graduate Program in Immunology, University of Iowa Carver College of Medicine, Veterans Affairs Health Care System, 601 Highway 6 West, Research (151), Iowa City, IA, 52246, USA
Craig T. Morita

Authors

Yoshimasa Tanaka
View author publications
You can also search for this author in PubMed Google Scholar
Masashi Iwasaki
View author publications
You can also search for this author in PubMed Google Scholar
Kaoru Murata-Hirai
View author publications
You can also search for this author in PubMed Google Scholar
Kenji Matsumoto
View author publications
You can also search for this author in PubMed Google Scholar
Kosuke Hayashi
View author publications
You can also search for this author in PubMed Google Scholar
Haruki Okamura
View author publications
You can also search for this author in PubMed Google Scholar
Tomoharu Sugie
View author publications
You can also search for this author in PubMed Google Scholar
Nagahiro Minato
View author publications
You can also search for this author in PubMed Google Scholar
Craig T. Morita
View author publications
You can also search for this author in PubMed Google Scholar
Masakazu Toi
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

Y.T. designed the research. Y.T., M.I. and K.M.H. performed biological experiments. Y.T., K.M. and K.H. synthesized bisphosphonate prodrugs and acids. H.O., T.S., N.M., C.T.M. and M.T. wrote the manuscript with Y.T. All authors discussed the results and commented on the manuscript.

Corresponding author

Correspondence to Yoshimasa Tanaka.

Ethics declarations

Competing Interests

C.T.M. is a co-inventor of US Patent 8,012,466 on the development of live bacterial vaccines for activating γδ T cells and has no other financial or non-financial conflict of interest. The other authors declare no financial or non-financial conflict of interest.

Additional information

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Supplementary Information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Tanaka, Y., Iwasaki, M., Murata-Hirai, K. et al. Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug. Sci Rep 7, 5987 (2017). https://doi.org/10.1038/s41598-017-05553-0

Download citation

Received: 17 January 2017
Accepted: 31 May 2017
Published: 20 July 2017
DOI: https://doi.org/10.1038/s41598-017-05553-0

This article is cited by

Human Vγ9Vδ2 T cell expansion and their cytotoxic responses against cholangiocarcinoma
- Piamsiri Sawaisorn
- Ahmed Gaballa
- Kulachart Jangpatarapongsa
Scientific Reports (2024)
Synthesis of C(28)-linker derivatives of betulinic acid bearing phosphonate group
- O. V. Tsepaeva
- A. V. Nemtarev
- V. F. Mironov
Russian Chemical Bulletin (2021)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.